ABOUT - History
Galenea was founded on the ground-breaking work of Professors Susumu Tonegawa and Dr. David Gerber at the Massachusetts Institute of Technology and Maria Karayiorgou at Columbia University Medical Center (formerly at The Rockefeller University). Together, their laboratories obtained both behavioral and genetic evidence for the role of calcineurin in the pathogenesis of schizophrenia. These discoveries led to the founding collaboration between Galenea and Otsuka Pharmaceuticals that was the exclusive focus of the company from 2005 until the successful conclusion of the collaboration and transfer of two small molecule programs at the end of 2011.
Through our work on the role of calcineurin in synaptic transmission, we conceived of and built a platform technology which permits us to assess communication between neurons at the cellular and network levels. This discovery platform has now generated a therapeutics program for cognitive impairment, and discovery programs in Huntington's disease and neurodegeneration.